{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T19:18:39Z","timestamp":1785007119312,"version":"3.55.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2020,4,1]]},"DOI":"10.1001\/jamaneurol.2019.4565","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T16:01:19Z","timestamp":1578931279000},"page":"461","source":"Crossref","is-referenced-by-count":63,"title":["Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults"],"prefix":"10.1001","volume":"77","author":[{"given":"Stuart H.","family":"Isaacson","sequence":"first","affiliation":[{"name":"Parkinson\u2019s Disease and Movement Disorder Center of Boca Raton, Boca Raton, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Ondo","sequence":"additional","affiliation":[{"name":"Houston Methodist Neurological Institute, Houston, Texas"},{"name":"Weill Cornell Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlayne E.","family":"Jackson","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center, San Antonio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Trosch","sequence":"additional","affiliation":[{"name":"Franklin Neurology, Farmington Hills, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Molho","sequence":"additional","affiliation":[{"name":"Parkinson\u2019s Disease and Movement Disorder Center, Albany Medical Center, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Pagan","sequence":"additional","affiliation":[{"name":"Georgetown University Medical Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lew","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashayar","family":"Dashtipour","sequence":"additional","affiliation":[{"name":"Loma Linda University Schools of Medicine and Pharmacy, Loma Linda, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Clinch","sequence":"additional","affiliation":[{"name":"US WorldMeds LLC, Louisville, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.","family":"Espay","sequence":"additional","affiliation":[{"name":"James J. and Joan A. Gardner Family Center for Parkinson\u2019s Disease and Movement Disorders, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the MYSTICOL Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"noi190108r1","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00415-009-5098-2","article-title":"Prevalence and definition of drooling in Parkinson\u2019s disease: a systematic review.","volume":"256","author":"Kalf","year":"2009","journal-title":"J Neurol"},{"issue":"11","key":"noi190108r2","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/mds.23135","article-title":"Parkinson\u2019s disease symptoms: the patient\u2019s perspective.","volume":"25","author":"Politis","year":"2010","journal-title":"Mov Disord"},{"issue":"2","key":"noi190108r3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/mus.v39:2","article-title":"Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients.","volume":"39","author":"Jackson","year":"2009","journal-title":"Muscle Nerve"},{"issue":"11","key":"noi190108r4","first-page":"2628","article-title":"Sialorrhea: a management challenge.","volume":"69","author":"Hockstein","year":"2004","journal-title":"Am Fam Physician"},{"issue":"16","key":"noi190108r5","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1002\/mds.v22:16","article-title":"Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism.","volume":"22","author":"Postma","year":"2007","journal-title":"Mov Disord"},{"issue":"7","key":"noi190108r6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.parkreldis.2009.12.003","article-title":"The impact of and the factors associated with drooling in Parkinson\u2019s disease.","volume":"16","author":"Leibner","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"noi190108r7","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1517\/14656566.6.9.1551","article-title":"Controlling sialorrhoea: a review of available treatment options.","volume":"6","author":"Potulska","year":"2005","journal-title":"Expert Opin Pharmacother"},{"issue":"1-2","key":"noi190108r8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2005.04.017","article-title":"Expanding use of botulinum toxin.","volume":"235","author":"Bhidayasiri","year":"2005","journal-title":"J Neurol Sci"},{"issue":"1","key":"noi190108r9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1212\/WNL.54.1.244","article-title":"Botulinum toxin A as treatment for drooling saliva in PD.","volume":"54","author":"Pal","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"noi190108r10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1212\/01.WNL.0000101713.81253.4C","article-title":"A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson\u2019s disease.","volume":"62","author":"Ondo","year":"2004","journal-title":"Neurology"},{"issue":"2","key":"noi190108r11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/0194599812465059","article-title":"Botulinum toxin for the treatment of sialorrhea: a meta-analysis.","volume":"148","author":"Vashishta","year":"2013","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"5","key":"noi190108r14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.toxicon.2009.03.009","article-title":"NeuroBloc\/Myobloc: unique features and findings.","volume":"54","author":"Arezzo","year":"2009","journal-title":"Toxicon"},{"issue":"pt A","key":"noi190108r15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.toxicon.2015.08.001","article-title":"Clinical differences between botulinum neurotoxin type A and B.","volume":"107","author":"Bentivoglio","year":"2015","journal-title":"Toxicon"},{"key":"noi190108r16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40734-017-0055-1","article-title":"RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials.","volume":"4","author":"Dashtipour","year":"2017","journal-title":"J Clin Mov Disord"},{"issue":"9","key":"noi190108r17","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"issue":"20","key":"noi190108r18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"noi190108r19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/105294199277860","article-title":"The International Conference on Harmonization Good Clinical Practice guideline.","volume":"6","author":"Dixon","year":"1998","journal-title":"Qual Assur"},{"issue":"2","key":"noi190108r20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/mds.v20:2","article-title":"Salivary production in Parkinson\u2019s disease.","volume":"20","author":"Proulx","year":"2005","journal-title":"Mov Disord"},{"issue":"2","key":"noi190108r21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF02412423","article-title":"Three treatment approaches and clinical factors in the reduction of drooling.","volume":"3","author":"Thomas-Stonell","year":"1988","journal-title":"Dysphagia"},{"issue":"2","key":"noi190108r22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/practneurol-2016-001515","article-title":"Management of oral secretions in neurological disease.","volume":"17","author":"McGeachan","year":"2017","journal-title":"Pract Neurol"},{"issue":"5","key":"noi190108r23","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3390\/toxins5051010","article-title":"Sialorrhea: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins.","volume":"5","author":"Lakraj","year":"2013","journal-title":"Toxins (Basel)"},{"issue":"17","key":"noi190108r24","doi-asserted-by":"publisher","first-page":"e1982","DOI":"10.1212\/WNL.0000000000007368","article-title":"SIAXI: placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.","volume":"92","author":"Jost","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"noi190108r25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/mds.23929","article-title":"Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson\u2019s disease: a prospective double-blind trial.","volume":"27","author":"Chinnapongse","year":"2012","journal-title":"Mov Disord"},{"issue":"4","key":"noi190108r26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00415-009-0085-1","article-title":"Long-lasting benefits of botulinum toxin type B in Parkinson\u2019s disease-related drooling.","volume":"256","author":"Lagalla","year":"2009","journal-title":"J Neurol"},{"issue":"4","key":"noi190108r27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00213-009-1689-y","article-title":"Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea.","volume":"207","author":"Steinlechner","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"noi190108r28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mds.23473","article-title":"Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson\u2019s disease.","volume":"26","author":"Guidubaldi","year":"2011","journal-title":"Mov Disord"},{"issue":"1","key":"noi190108r29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/ipd.12156","article-title":"Association of onabotulinum toxin A treatment with salivary pH and dental caries of neurologically impaired children with sialorrhea.","volume":"26","author":"Ferraz Dos Santos","year":"2016","journal-title":"Int J Paediatr Dent"},{"key":"noi190108r30","article-title":"Periodontal health and caries prevalence evaluation in patients affected by Parkinson\u2019s disease.","volume":"2012","author":"Cicci\u00f9","year":"2012","journal-title":"Parkinsons Dis"},{"key":"noi190108r31","first-page":"38","article-title":"Ultrastructural changes in the parotid gland of rats after intraglandular injection of botulinum toxin A.","volume":"1(4)","author":"Younis","year":"2013","journal-title":"Ann Oral & Maxillofac Surg"},{"key":"noi190108r12","unstructured":"Drugs@FDA. Highlights of prescribing information: xeomin. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125360s074lbl.pdf. Accessed December 2, 2019."},{"key":"noi190108r13","unstructured":"Drugs@FDA. FDA approved drug products: BLA 103846. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=103846. Accessed December 2, 2019."}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2758316\/jamaneurology_isaacson_2020_oi_190108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T15:01:16Z","timestamp":1586790076000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2758316"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2019.4565","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}